stockrowGilead Sciences, Inc.
GILD Healthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024.
- Revenue
- +6.83%
- EPS
- −20.5%
- Free cash flow
- +21.1%
- Total debt
- +5.17%
Quarter to September 2026, against a year earlier
Follow GILD
Alert me
Gilead Sciences, Inc. (GILD) Return on assets
Gilead Sciences, Inc.'s return on assets over the twelve months to 30 September 2026 was −7.03%, down 21.4 percentage points from fiscal 2025 (14.4%). Over the past ten years it has ranged from 0.19% (fiscal 2020) to 41.9% (fiscal 2015); the current reading is higher than 82% of that period. That is below the Drug Manufacturers General industry median of 2.28% and above the Healthcare sector median of −29.5%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 14.4% | 13.63 |
| FY2024 | 0.79% | (8.25) |
| FY2023 | 9.04% | 2.04 |
| FY2022 | 7.00% | (2.13) |
| FY2021 | 9.13% | 8.94 |
| FY2020 | 0.19% | (8.41) |
| FY2019 | 8.60% | 0.46 |
| FY2018 | 8.14% | 0.87 |
| FY2017 | 7.27% | (17.57) |
| FY2016 | 24.8% | (17.09) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| NVO Novo Nordisk A/S compare | 20.5% |
| AMGN Amgen Inc. compare | 10.1% |
| BMY Bristol Myers Squibb Company compare | 9.96% |
| AZN AstraZeneca PLC compare | 9.41% |
| NVS Novartis AG compare | 8.94% |
| SNY Sanofi compare | 3.24% |
| PFE Pfizer Inc. compare | 1.95% |
| MRK Merck & Co., Inc. compare | 1.87% |
| GILD Gilead Sciences, Inc. | −7.03% |
| Drug Manufacturers General industry median | 2.28% |
| Healthcare sector median | −29.5% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on GILD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement